Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 9/20 | 0.83 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.83 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.83 |
| ▸ | PGR | P06401 | 1/20 | 0.83 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.83 |
| ▸ | PDE4A | P27815 | 1/20 | 0.83 |
| ▸ | BLVRB | P30043 | 1/20 | 0.83 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.83 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.83 |
| ▸ | PPID | Q08752 | 1/20 | 0.66 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Febuxostat SCHEMBL249339 | 0.91 | XDH (1.00) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL16363788 | 0.91 | XDH (0.85) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL30161803 | 0.91 | XDH (1.00) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL29398803 | 0.91 | XDH (1.00) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL28271887 | 0.91 | XDH (1.00) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL23390995 | 0.90 | XDH (0.83) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL27935497 | 0.90 | XDH (0.98) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL2635992 | 0.90 | XDH (0.83) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL27935500 | 0.90 | XDH (0.98) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL28130756 | 0.90 | XDH (0.83) | XDHTARBP2ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160332950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND GOUT | ALAPATI MOHAN MURALI (IN) | 2016-11-17 | — | — | US | disclosed |
| US-9475747-B1 | Compositions and methods for the treatment of urea cycle disorders and gout | ALAPATI MOHAN MURALI (IN) | 2016-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND GOUT | SLC14A1, UMPS, UGT1A3 | XDH 18/4885TARBP2 466/4885ABCC4 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.